Skip to main content
. 2021 Jul 9;12(7):808. doi: 10.3390/mi12070808

Table 2.

The clinical samples analysis data for determination of doxorubicin using ds-DNA/SWCNTs/GCE as a new biosensor (n = 4).

Sample Doxorubicin Added (µM) Doxorubicin
Expected (µM)
Doxorubicin Founded (µM) Recovery%
(Doxorubicin Founded/Doxorubicin
Expected) * 100
Injection - 1.00 1.03 ± 0.05 103
- 9.00 10.00 9.72 ± 0.53 97.2
dextrose saline - - <Limit of detection -
- 10.00 10.00 9.82 ± 0.53 98.2
- 15.00 15.00 15.74 ± 0.86 104.9
HHS Vulnerability Disclosure